We are interested in the mechanisms employed by pathogenic Clostridia to cause disease. We use molecular microbiology and other approaches to identify and characterise novel virulence factors, which may lead to their exploitation as targets for novel therapeutics. Currently the main focus of my lab is Clostridium difficile, which causes gastrointesinal infections of man and animals and which is particularly problematic in hospitals.
Our group is a member of the Centre for Molecular Bacteriology and Infection (CMBI) and the Centre for Infection Prevention and Management who share well funded facilities and a common interest in bacterial pathogenesis.
et al., 2012, A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice, Vaccine, Vol:30, ISSN:0264-410X, Pages:3047-3052
et al., 2012, Novel inhibitors of surface layer processing in Clostridium difficile, Bioorganic & Medicinal Chemistry, Vol:20, ISSN:0968-0896, Pages:614-621
Fagan RP, Fairweather NF, 2011, Clostridium difficile Has Two Parallel and Essential Sec Secretion Systems, Journal of Biological Chemistry, Vol:286, ISSN:0021-9258, Pages:27483-27493
Dembek M, Reynolds CB, Fairweather NF, 2012, Clostridium difficile Cell Wall Protein CwpV Undergoes Enzyme-independent Intramolecular Autoproteolysis, Journal of Biological Chemistry, Vol:287, ISSN:0021-9258, Pages:1538-1544
et al., 2013, Transcriptional Analysis of Temporal Gene Expression in Germinating Clostridium difficile 630 Endospores, PLOS One, Vol:8, ISSN:1932-6203
et al., 2009, A novel genetic switch controls phase variable expression of CwpV, a Clostridium difficile cell wall protein, Molecular Microbiology, Vol:74, ISSN:0950-382X, Pages:541-556